183 related articles for article (PubMed ID: 9312195)
1. Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial.
Boutsen Y; Jamart J; Esselinckx W; Stoffel M; Devogelaer JP
Calcif Tissue Int; 1997 Oct; 61(4):266-71. PubMed ID: 9312195
[TBL] [Abstract][Full Text] [Related]
2. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
[TBL] [Abstract][Full Text] [Related]
3. Prevention of osteoporosis in heart transplant recipients: a comparison of calcitriol with calcitonin and pamidronate.
Bianda T; Linka A; Junga G; Brunner H; Steinert H; Kiowski W; Schmid C
Calcif Tissue Int; 2000 Aug; 67(2):116-21. PubMed ID: 10920215
[TBL] [Abstract][Full Text] [Related]
4. Intermittent oral disodium pamidronate in established osteoporosis: a 2 year double-masked placebo-controlled study of efficacy and safety.
Ryan PJ; Blake GM; Davie M; Haddaway M; Gibson T; Fogelman I
Osteoporos Int; 2000; 11(2):171-6. PubMed ID: 10793877
[TBL] [Abstract][Full Text] [Related]
5. Site-dependent bone mineral density response to oral pamidronate and calcium in postmenopausal osteoporosis: a preliminary report.
Barreira JC; Messina OD; Maldonado-Cocco JA; Roldan EJ
Clin Rheumatol; 1997 Jun; 16(4):346-52. PubMed ID: 9259247
[TBL] [Abstract][Full Text] [Related]
6. Pamidronate increases bone mineral density in women with postmenopausal or steroid-induced osteoporosis.
Cauza E; Etemad M; Winkler F; Hanusch-Enserer U; Partsch G; Noske H; Dunky A
J Clin Pharm Ther; 2004 Oct; 29(5):431-6. PubMed ID: 15482386
[TBL] [Abstract][Full Text] [Related]
7. Role of oral pamidronate in preventing bone loss in postmenopausal women.
Lees B; Garland SW; Walton C; Ross D; Whitehead MI; Stevenson JC
Osteoporos Int; 1996; 6(6):480-5. PubMed ID: 9116394
[TBL] [Abstract][Full Text] [Related]
8. The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis.
Vis M; Bultink IE; Dijkmans BA; Lems WF
Osteoporos Int; 2005 Nov; 16(11):1432-5. PubMed ID: 15883662
[TBL] [Abstract][Full Text] [Related]
9. Dual energy X-ray absorptiometry outcomes in male COPD patients after treatment with different glucocorticoid regimens.
Dubois EF; Röder E; Dekhuijzen PN; Zwinderman AE; Schweitzer DH
Chest; 2002 May; 121(5):1456-63. PubMed ID: 12006428
[TBL] [Abstract][Full Text] [Related]
10. Intravenous pamidronate as treatment for osteoporosis after heart transplantation: a prospective study.
Krieg MA; Seydoux C; Sandini L; Goy JJ; Berguer DG; Thiébaud D; Burckhardt P
Osteoporos Int; 2001; 12(2):112-6. PubMed ID: 11303710
[TBL] [Abstract][Full Text] [Related]
11. Differential action of pamidronate on trabecular and cortical bone in women with involutional osteoporosis.
Fromm GA; Vega E; Plantalech L; Galich AM; Mautalen CA
Osteoporos Int; 1991 Jun; 1(3):129-33. PubMed ID: 1790400
[TBL] [Abstract][Full Text] [Related]
12. Low-dose pamidronate for treatment of early bone loss following kidney transplantation: a randomized controlled trial.
Shahidi S; Ashrafi F; Mohammadi M; Moeinzadeh F; Atapour A
Iran J Kidney Dis; 2015 Jan; 9(1):50-5. PubMed ID: 25599737
[TBL] [Abstract][Full Text] [Related]
13. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
Smith MR; McGovern FJ; Zietman AL; Fallon MA; Hayden DL; Schoenfeld DA; Kantoff PW; Finkelstein JS
N Engl J Med; 2001 Sep; 345(13):948-55. PubMed ID: 11575286
[TBL] [Abstract][Full Text] [Related]
14. Pamidronate therapy as prevention of bone loss following renal transplantation.
Fan SL; Almond MK; Ball E; Evans K; Cunningham J
Kidney Int; 2000 Feb; 57(2):684-90. PubMed ID: 10652047
[TBL] [Abstract][Full Text] [Related]
15. Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause.
Thiébaud D; Burckhardt P; Melchior J; Eckert P; Jacquet AF; Schnyder P; Gobelet C
Osteoporos Int; 1994 Mar; 4(2):76-83. PubMed ID: 8003844
[TBL] [Abstract][Full Text] [Related]
16. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
McClung MR; Wasnich RD; Recker R; Cauley JA; Chesnut CH; Ensrud KE; Burdeska A; Mills T;
J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
[TBL] [Abstract][Full Text] [Related]
17. Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate.
Kananen K; Volin L; Laitinen K; Alfthan H; Ruutu T; Välimäki MJ
J Clin Endocrinol Metab; 2005 Jul; 90(7):3877-85. PubMed ID: 15797959
[TBL] [Abstract][Full Text] [Related]
18. A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease.
Bartram SA; Peaston RT; Rawlings DJ; Francis RM; Thompson NP
Aliment Pharmacol Ther; 2003 Dec; 18(11-12):1121-7. PubMed ID: 14653832
[TBL] [Abstract][Full Text] [Related]
19. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis.
Thiébaud D; Burckhardt P; Kriegbaum H; Huss H; Mulder H; Juttmann JR; Schöter KH
Am J Med; 1997 Oct; 103(4):298-307. PubMed ID: 9382122
[TBL] [Abstract][Full Text] [Related]
20. Effects of prolonged bisphosphonate therapy and its discontinuation on bone mineral density in post-menopausal osteoporosis.
Orr-Walker B; Wattie DJ; Evans MC; Reid IR
Clin Endocrinol (Oxf); 1997 Jan; 46(1):87-92. PubMed ID: 9059563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
